[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335058-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335058-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","spatial-molecular-profiling-of-mixed-invasive-ductal-and-lobular-breast-cancers-reveals-heterogeneity-in-intrinsic-molecular-subtypes-oncogenic-signatures-and-mutations","Spatial molecular profiling of mixed invasive ductal and lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations","","Mixed invasive ductal and lobular carcinoma (MDLC) is a rare breast cancer subtype combining E-cadherin-positive ductal and E-cadherin-negative lobular morphologies within the same tumor, complicating clinical management and recurrence risk assessment. Spatially resolved transcriptomic, genomic, and single-cell profiling uncovers clinically significant differences between ductal and lobular regions, including intrinsic subtype heterogeneity, distinct oncogenic and cell-cycle/senescence enrichments, and region-specific CDH1 inactivation. Single-cell analyses further identify unique ductal and lobular subpopulations, supporting intraregional molecular heterogeneity that can drive prognostic uncertainty and therapeutic dilemmas.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/spatial-molecular-profiling-of-mixed-invasive-ductal-and-lobular-breast-cancers-reveals-heterogeneity-in-intrinsic-molecular-subtypes-oncogenic-signatures-and-mutations/335058/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/spatial-molecular-profiling-of-mixed-invasive-ductal-and-lobular-breast-cancers-reveals-heterogeneity-in-intrinsic-molecular-subtypes-oncogenic-signatures-and-mutations/335058.png","ImageObject",300,407,{"name":42,"@type":43},"Liam","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-22","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What makes mixed invasive ductal and lobular carcinoma (MDLC) challenging to manage clinically?","Question",{"text":63,"@type":64},"MDLC contains both E-cadherin-positive ductal and E-cadherin-negative lobular morphologies within the same tumor, and it was unclear whether these regions differ biologically or in recurrence risk.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the study characterize differences between ductal and lobular tumor regions?",{"text":68,"@type":64},"It used spatially resolved transcriptomic, genomic, and single-cell profiling to compare clinically relevant differences across regions.",{"name":70,"@type":61,"acceptedAnswer":71},"What molecular heterogeneity was observed within MDLC?",{"text":72,"@type":64},"Ductal and lobular regions showed distinct intrinsic subtype heterogeneity, enrichment of cell cycle arrest/senescence and oncogenic signatures, and region-specific genetic/epigenetic CDH1 inactivation in lobular but not ductal regions.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335058,1790073845,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","RESEARCH ARTICLE  \nGENETICS  \nBIOPHYSICS AND COMPUTATIONAL BIOLOGY  \nSpatial molecular profiling of mixed invasive ductal and lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations  \nOsama Shiraz Shaha, b , Azadeh Nasrazadania,c, Julia Foldid , Jennifer M. Atkinsona,e, Celina G. Kleerf, Priscilla F. McAuliffea,g, Tyler J. Johnstonh , Wayne Stallaerth, Edaise M. da Silvai , Pier Selenicai, Higinio Dopesoi , Fresia Parejai, Diana Mandelkeri, Britta Weigelti, Jorge S. Reis-Filhoi,1,  \nRohit Bhargavac , Peter C. Lucasj , Adrian V. Leea,e,2, and Steffi Oesterreicha,e,2 Affiliations are included on p. 10.  \nEdited by Myles Brown, Dana-Farber Cancer Institute, Boston, MA; received December 28, 2023; accepted June 13, 2024  \nMixed invasive ductal and lobular carcinoma (MDLC) is a rare histologic subtype of breast cancer displaying bothE-cadherin positive ductal andE-cadherin negative lobular morphologies within the same tumor, posing challenges with regard to anticipated clinical management. It remains unclear whether these distinct morphologies also have distinct biology and risk of recurrence. Our spatially resolved transcriptomic, genomic, and single-cell profiling revealed clinically significant differences between ductal and lobular tumor regions including distinct intrinsic subtype heterogeneity – e.g., MDLC with triple-negative breast cancer (TNBC) or basal ductal and estrogen receptor positive (ER+) luminallobular regions, distinct enrichment of cell cycle arrest/senescence and oncogenic (ERand MYC) signatures, genetic and epigenetic CDH1 inactivation in lobular but not ductal regions, and single-cell ductaland lobular subpopulations with unique oncogenic signatures further highlighting intraregional heterogeneity. Altogether, we demonstrated that the intratumoral morphological/ histological heterogeneity within MDLCis underpinned by intrinsic subtype and oncogenic heterogeneity which may result in prognostic uncertainty and therapeutic dilemma.  \nbreast cancer | mixed ductal–lobular carcinoma | tumor heterogeneity | single cell omics | spatial transcriptomics  \nBreast cancer is a prevalent disease worldwide (1) and is the most frequently diagnosed cancer in women in the United States, with approximately 300,000 cases per year (2). The majority (approximately 75%) of cases are classified histologically as invasive breast carcinoma of no special type (IBC-NST), previously described as invasive ductal cancer (IDC) . Invasive lobular carcinoma (ILC) is the most common special type accounting for approximately 10 to 15% of all invasive breast cancer diagnoses (3, 4). Apart from the well-defined histologic and tissue histological differences, there are numerous notable molecular distinctions between ILCand IBC-NST. ILC exhibits enrichment ofCDH1, FOXA1, TBX3, ERBB2, and PTEN alterations, while IBC-NST shows a higher frequency of GATA3, MAP3K1, TP53, and MYC alterations (5) . As a result of CDH1 alterations, ILC lacks expression of E-cadherin, an important cell adhesion molecule (4), and displays cytoplasmic p120 staining while IBC-NST retains membranous expression for both molecules (6) . Clinically, ILC is more common in elderly women, presents as larger tumors, and is frequently multicentric and multifocal compared to IBC-NST (7, 8). ILC is usually detected later and leads to higher rates of mastectomy (7–11). ILC is also associated with more frequent metastases to urogenital and gastrointestinal tracts as well as to serosal surfaces than IBC-NST (12, 13) . Despite presenting with markers of favorable prognosis, such as low grade, low proliferation index, estrogen receptor positive (ER+), and human epidermal growth factor receptor (HER2) low/ negative, patients with ILC have a higher rate of late recurrences and worse long-term prognosis than those with IBC-NST (8, 14, 15). Given its distinct prognosis and outcome compared to IBC-NST, ILC is increasingly being recognized ","cbCaip6Q6Oa7I13c","https://ap.wps.com/l/cbCaip6Q6Oa7I13c","pdf",4452850,11,"English","# Mixed invasive ductal and lobular carcinoma (MDLC)\n## Spatial multi-omic profiling approach\n## Key findings: intrinsic subtypes, oncogenic signatures, and mutations\n## Significance and clinical implications","[{\"question\":\"What makes mixed invasive ductal and lobular carcinoma (MDLC) challenging to manage clinically?\",\"answer\":\"MDLC contains both E-cadherin-positive ductal and E-cadherin-negative lobular morphologies within the same tumor, and it was unclear whether these regions differ biologically or in recurrence risk.\"},{\"question\":\"How did the study characterize differences between ductal and lobular tumor regions?\",\"answer\":\"It used spatially resolved transcriptomic, genomic, and single-cell profiling to compare clinically relevant differences across regions.\"},{\"question\":\"What molecular heterogeneity was observed within MDLC?\",\"answer\":\"Ductal and lobular regions showed distinct intrinsic subtype heterogeneity, enrichment of cell cycle arrest/senescence and oncogenic signatures, and region-specific genetic/epigenetic CDH1 inactivation in lobular but not ductal regions.\"}]","Spatial molecular profiling of mixed invasive ductal and lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations | PDF",1790009514,28]